Phase 1 Alopecia Clinical Trials
8 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–8 of 8 trials
Recruiting
Phase 1
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
HealthySevere Alopecia AreataActive Non-segmental Vitiligo
Innovent Biologics (Suzhou) Co. Ltd.160 enrolled1 locationNCT07554222
Recruiting
Phase 1Phase 2
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
Alopecia Areata (AA)
Aldena Therapeutics24 enrolled7 locationsNCT06826196
Recruiting
Phase 1
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
Alopecia AreataVitiligo
Dren Bio80 enrolled20 locationsNCT06602232
Recruiting
Phase 1
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Alopecia Areata
Forte Biosciences, Inc.32 enrolled6 locationsNCT07205159
Recruiting
Phase 1
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Otsuka Pharmaceutical Development & Commercialization, Inc.30 enrolled6 locationsNCT06799520
Recruiting
Phase 1Phase 2
Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser
Alopecia Areata
Egymedicalpedia70 enrolled1 locationNCT06239324
Active
Phase 1
The effect of sublingual minoxidil in trans people with androgenic alopecia receiving testosterone for gender-affirmation
Androgenic alopecia
The University of Melbourne32 enrolled1 locationACTRN12623000356662
Completed
Phase 1
A single-center study of the safety, tolerability and pharmacokinetics of a single concentration of topical SM04554 (0.25% concentration) solution in male subjects with androgenetic alopecia.
Androgenetic alopecia (AGA)
Samumed Pacific Pty Ltd25 enrolled1 locationACTRN12615000980538